{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EU ORPHAN DRUG|Positive" in comments (approximate match)
Status:
Investigational
Source:
INN:efpegerglucagon [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04317040: Phase 3 Interventional Completed Coronavirus Disease 2019 (COVID-19)
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02869243: Phase 1 Interventional Completed Glioblastoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:grisnilimab setaritox [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03406611: Phase 1/Phase 2 Interventional Active, not recruiting Homocystinuria
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04111484: Not Applicable Interventional Completed Headache, Migraine
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:dafsolimab setaritox [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04627025: Phase 3 Interventional Completed Short Bowel Syndrome
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02605525: Phase 2 Interventional Withdrawn Immunoglobulin A Nephropathy
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03902184: Phase 2 Interventional Active, not recruiting Lymphoma, T-Cell
(2019)
Source URL:
Class:
PROTEIN
